Novartis sees no benefit of Adakveo for sickle cell

 

Novartis (NYSE:NVS) said that a phase 3 trial of Advakeo (crizanlizumab), which is used to treat vaso-occlusive crises, did not show any benefit in sickle cell disease in a Phase 3 trial.

https://seekingalpha.com/news/3929011-novartis-sees-no-benefit-of-adakveo-for-sickle-cell-ailment-in-phase-3-trial